Ownership history in Affinity Asset Advisors, LLC Β· 14 quarters on record
This page tracks every 13F SEC filing in which Affinity Asset Advisors, LLC reported a position in CONTEXT THERAPEUTICS INC (CNTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Affinity Asset Advisors, LLC underperformed the S&P 500 by β19.6% annually on this CNTX position. Timing score: 33% (3/9 decisions correct). Average cost basis: $2.06. Maximum drawdown during holding period: β71.9%.
β Significantly underperformed the S&P 500 by 19.6% ann.
9 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
3 of 9 add/trim decisions correct
Best entry: $1.51 (2023 Q3) Β· Worst: $2.17 (2022 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
4 adds Β· 6 trims. Bought during 2 of 8 down-price quarters. π Predominantly trimming β distribution phase.
π Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 0.03% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size